Immune Thrombocytopenia Market is Anticipated to Grow by 2030 Owing to a Rich and Robust Pipeline

- The expected launch of upcoming therapies in the Immune Thrombocytopenia (ITP) market viz. a viz., BT595 (Biotest) in 2021; UCB7665 (UCB Biopharma) in and ARGX-113 (Argenx BVBA) along with many more in 2023 is going to influence the ITP market positively

LAS VEGAS, May 27, 2020 /PRNewswire/ -- DelveInsight has added a new report Immune Thrombocytopenia (ITP) Market Insights, Epidemiology and Market Forecast—2030 in its vast repository of market research reports.

Key Highlights:

• The total Immune Thrombocytopenia prevalent population in the 7MM is expected to reach up to 184,676 in 2020.
• The Immune Thrombocytopenia market size in the 7MM was be USD 2,527.72 million in 2017.
• Key pharma companies fuelling the ITP market are Octapharma USA, Amgen, CSL Behring, Dova Pharmaceuticals, Rigel Pharmaceuticals, Zenyaku Kogyo/Biogen Idec, Novartis, Bio Products Laboratory's, Takeda Pharmaceutical Company Limited, AstraZeneca, Biotest, GC Pharma, SK Plasma, Jiangsu HengRui Medicine, Argenx, Genosco (a US-based subsidiary of Korean bio company Oscotec), Kezar Life Sciences, UCB Biopharma, Bristol-Myers Squibb, Principia Biopharma, Protalex and others.

Request for the Sample Pages: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market

Immune thrombocytopenia, earlier known as immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when body attacks its own platelets and destroys them too quickly.

Immune Thrombocytopenia Epidemiology

The United States is expected to account for the maximum prevalent Immune Thrombocytopenia cases among 7MM countries by 2020. Among the European countries, the United Kingdom will have the highest ITP prevalent population, whereas Spain would account for the lowest ITP prevalent population. Japan, however, is expected to record for the least Immune Thrombocytopenia prevalence in the 7MM.

ITP can be further of two main types - Acute (short term) and Chronic (long term). ITP is also categorized as primary and secondary based on the cause of the disease.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by:

• Total Prevalent Population of ITP,
• Total Diagnosed Prevalent Population of ITP, and
• Gender-specific Diagnosed Prevalent Population of ITP scenario

Visit to Know More about the Report: https://www.delveinsight.com/report-store/immune-thrombocytopenia-market